Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts

Boston Scientific (BSX) ended the recent trading session at $49.11, demonstrating a -2.68% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.58%. Meanwhile, the Dow gained 0.05%, and the Nasdaq, a tech-heavy index, added 0.91%. The medical device manufacturer's stock has dropped by 11.71% in the past month, falling short of the Medical sector's gain of 2.82% and the S&P 500's gain of 4.96%.The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. On that day, Boston Scientific is projected to report earnings of $0.84 per share, which would represent year-over-year growth of 12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.41 billion, up 6.82% from the year-ago period. BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.37 per share and revenue of $21.67 billion. These results would represent year-over-year changes of +10.13% and +7.95%, respectively. It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.09% decrease. At present, Boston Scientific boasts a Zacks Rank of #4 (Sell). In terms of valuation, Boston Scientific is presently being traded at a Forward P/E ratio of 14.96. This valuation marks a discount compared to its industry average Forward P/E of 18.52. We can also see that BSX currently has a PEG ratio of 0.93. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Products industry had an average PEG ratio of 1.52. The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 155, putting it in the bottom 37% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks